ArticleThe Lancet regional health. Southeast Asia2026
Cost-effectiveness of a mTB-Tobacco intervention for smoking cessation in people with tuberculosis: an economic evaluation of a cluster randomised controlled trial.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High prevalence of smoking tobacco among people with tuberculosis (TB) contribute towards poor outcomes in low- and middle-income countries. A mobile phone-based intervention for smoking cessation among this population (mTB-Tobacco) was evaluated for its cost-effectiveness alongside a cluster randomised controlled trial in Pakistan and Bangladesh. Methods: A two-arm superiority cluster randomised controlled trial with 6 months follow up was conducted between September 2023 and January 2025 in Dhaka, Bangladesh and Punjab, Pakistan. The trial compared the mTB-Tobacco intervention with usual care as control. Participants included those older than or equal to 15 years of age, diagnosed with drug-sensitive pulmonary TB in the past 4 weeks, smoked tobacco daily but willing to quit, and had access to mobile phones. Eighteen TB health facilities (cluster) were randomised to mTB-Tobacco group (n = 720 participants) and nine to usual care (n = 360 participants). The primary analysis was an incremental cost-utility analysis from a public/voluntary sector perspective and primary outcome measure was Quality-Adjusted Life Years (QALYs). Total costs included the costs of TB treatment, costs of intervention or control, and costs of doctor visit and hospital stay. Secondary and sensitivity analyses were also conducted. Findings: Total costs were INT$ (international dollars) 36.17 (95% CI 3.65-65.81) higher and QALYs were 0.017 (95% CI 0.003-0.030) higher in mTB-Tobacco group than usual care group. Incremental cost-effectiveness ratio was calculated at INT$2127.64 per QALY gained. Estimates by country suggested mTB-Tobacco being unlikely cost-effective in Bangladesh (ICER = INT$4261.11 per QALY gained) but likely cost-effective in Pakistan (ICER = INT$1024.29 per QALY gained). Interpretation: If decision makers in the public/voluntary sector are willing to pay over INT$2100 for one additional QALY gained, mTB-Tobacco intervention could likely be cost-effective. Funding: The UK NIHR Global Health Research Unit on Respiratory Health (RESPIRE) (NIHR132826).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.